NEW YORK (GenomeWeb News) - Rosetta Genomics said today that it has licensed Nanogen’s MGB Probe technology for use with a line of microRNA biomarker-based diagnostic tests that it plans to launch in 2008.
Rosetta plans to use the MGB, or minor groove binder, probes to develop a line of real-time PCR-based diagnostic tests.
Rosetta said it expects to launch three tests in 2008: one that will differentiate squamous from non squamous lung cancers; another to differentiate mesothelioma from lung adenocarcinoma; and another to identify the origin of tumors in cancer cases where this is not known. The company said clinicians cannot identify the origin of metastases in between three and five percent of all cancer patients.
Financial terms of the licensing agreement with Nanogen were not disclosed.